ERBB2 and breast cancer: Given that BC is molecularly heterogeneous with many tumors expressing only moderate levels of multiple cell surface targets, including EGFR and HER2, we hypothesize that such tumors can be selectively targeted using combination PIT directed against EGFR and HER2 concurrently.